Mirum Pharmaceuticals to host investor call on AZURE-1 topline results

Mirum Pharmaceuticals will hold an investor call on Sept. 28, 2026 at 8:30 a.m. ET to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta. The company also plans to provide 48-week data from the Phase 2b portion of the study.